Volume 28, Issue 1 (3-2025)
J Arak Uni Med Sci 2025, 28(1): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadi E, Hooshmand L, Masumi A. Prevalence of Adverse Events and Hypoglycemia in Patients with Type 2 Diabetes Treated with Novel Antidiabetic Medications. J Arak Uni Med Sci 2025; 28 (1)
URL: http://jams.arakmu.ac.ir/article-1-7908-en.html
URL: http://jams.arakmu.ac.ir/article-1-7908-en.html
1- Department of Internal Medicine, University of Medical Sciences, Urmia, Iran , dremohammadi90@gmail.com
2- Department of Internal Medicine, University of Medical Sciences, Urmia, Iran
2- Department of Internal Medicine, University of Medical Sciences, Urmia, Iran
Abstract: (5 Views)
Background : Novel antidiabetic medications are employed to manage glycemic control and mitigate the long-term complications of type 2 diabetes. This study aimed to investigate the prevalence of adverse events, including hypoglycemia, associated with these novel antidiabetic agents in a cohort of patients with type 2 diabetes.
Methods: This cross-sectional analytical study was conducted on 157 patients with type 2 diabetes mellitus who were attending the Endocrinology Clinic at Imam Khomeini Hospital, Urmia, during the summer of 2024. A convenience sampling method was employed to recruit participants. Data on demographics, the incidence of hypoglycemia, and reported adverse drug reactions were collected from all eligible patients through a structured interview. Subsequently, patients were stratified into three treatment groups based on the specific novel antidiabetic medication they were receiving.
Results: In patients receiving sitagliptin, the most prevalent adverse events included arthralgia and rheumatic problems (26.31%), dermatological manifestations (36.84%), and allergic reactions (21.06%). Nausea (52.94%) and abdominal pain (17.65%) were the most frequent adverse events observed in patients treated with liraglutide. Polydipsia (28.72%), weakness and lethargy (26.6%), and dry mucous membranes (27.66%) were commonly reported in patients receiving empagliflozin. Hypoglycemia was observed predominantly in male patients aged 51-55 years receiving sitagliptin.
Conclusion: The findings of this study demonstrate a low incidence of hypoglycemia among patients treated with modern antidiabetic medications. Common short-term adverse events observed included gastrointestinal disturbances, allergic reactions, and dermatological manifestations.
Methods: This cross-sectional analytical study was conducted on 157 patients with type 2 diabetes mellitus who were attending the Endocrinology Clinic at Imam Khomeini Hospital, Urmia, during the summer of 2024. A convenience sampling method was employed to recruit participants. Data on demographics, the incidence of hypoglycemia, and reported adverse drug reactions were collected from all eligible patients through a structured interview. Subsequently, patients were stratified into three treatment groups based on the specific novel antidiabetic medication they were receiving.
Results: In patients receiving sitagliptin, the most prevalent adverse events included arthralgia and rheumatic problems (26.31%), dermatological manifestations (36.84%), and allergic reactions (21.06%). Nausea (52.94%) and abdominal pain (17.65%) were the most frequent adverse events observed in patients treated with liraglutide. Polydipsia (28.72%), weakness and lethargy (26.6%), and dry mucous membranes (27.66%) were commonly reported in patients receiving empagliflozin. Hypoglycemia was observed predominantly in male patients aged 51-55 years receiving sitagliptin.
Conclusion: The findings of this study demonstrate a low incidence of hypoglycemia among patients treated with modern antidiabetic medications. Common short-term adverse events observed included gastrointestinal disturbances, allergic reactions, and dermatological manifestations.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
